Why the study?
Do beta-blockers reduce morbidity and mortality in patients with congestive heart failure?
Do beta-blockers reduce morbidity and mortality in patients with congestive heart failure?
This review summarizes the evidence supporting the use of beta-blockers to reduce morbidity and mortality in patients with congestive heart failure.
Answers are grounded in this paper and cite their sources.
May support beta-blocker consideration in heart failure; extends prior data but leaves open practice change pending RCTs.
Recent advances in the understanding of the basic mechanisms underlying congestive heart failure (CHF) have focused on the role of neurohormonal activation. Chronic adrenergic overstimulation is directly toxic to myocardial cells, impairs function, causes peripheral vasoconstriction and may induce programmed cell death via apoptosis. beta-Adrenergic blockade can interrupt this pathological process. Accumulating evidence now points to a clear role for beta-blocking agents in the management of heart failure, reducing both the morbidity and mortality associated with CHF. This report will review the recent clinical trials supporting the use of beta-blockers in CHF, briefly highlight some practical considerations in the use of these drugs in patients with CHF and discuss several areas of controversy in which further study is needed.
No takes yet. Share an insight, caveat, or question.
Moskowitz et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: